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A higher oxidative stress may contribute to the pathogenesis of coronary artery disease (CAD). The purpose of this study was
to investigate the relationship between coenzyme Q10 concentration and lipid peroxidation, antioxidant enzymes activities and
the risk of CAD. Patients who were identiﬁed by cardiac catheterization as having at least 50% stenosis of one major coronary
artery were assigned to the case group (n = 51). The control group (n = 102) comprised healthy individuals with normal blood
biochemical values. The plasma coenzyme Q10, malondialdehyde (MDA) and antioxidant enzymes activities (catalase (CAT),
superoxide dismutase (SOD), glutathione peroxidase (GPx)) were measured. Subjects with CAD had signiﬁcant lower plasma
coenzyme Q10, CAT and GPx activities and higher MDA and SOD levels compared to those of the control group. The plasma
coenzyme Q10 was positively correlated with CAT and GPx activities and negatively correlated with MDA and SOD. However,
the correlations were not signiﬁcant after adjusting for the potential confounders of CAD with the exception of SOD. A higher
level of plasma coenzyme Q10 (≥0.52μmol/L) was signiﬁcantly associated with reducing the risk of CAD. Our results support the
potential cardioprotective impact of coenzyme Q10.
1.Introduction
Coenzyme Q10 (also called ubiquinone) is a lipid-soluble
benzoquinone with 10 isoprenyl units in the side chain and
is a key component of the mitochondrial respiratory chain
for adenosine triphosphate (ATP) synthesis [1, 2]. Coenzy-
meQ10isanintracellularantioxidantthatprotectsthemem-
brane phospholipids, mitochondrial membrane protein, and
low-density lipoprotein-cholesterol (LDL-C) from free radi-
cal-inducedoxidativedamage[3,4].Manystudies[5–7]have
indicated a relationship between low plasma coenzyme Q10
concentration and coronary artery disease (CAD), which
may contribute to the higher susceptibility of some individ-
uals to CAD, especially in Asian Indian and Chinese pop-
ulation [8]. However, the relationship between coenzyme
Q10 and the prevention of the risk of CAD are controversial.
Some studies reported the plasma coenzyme Q10 concentra-
tion was not related to the risk of coronary atherosclerosis,
and there was no beneﬁcial eﬀect of coenzyme Q10 in pa-
tients with CAD [9, 10].
Cardiovascular disease (CVD) is the leading cause of
deathworldwide.TheknowntraditionalriskfactorsforCAD
are smoking, obesity, hypertension, a family history of CAD,
diabetes mellitus, and hyperlipidemia. In addition to the
traditional CAD risk factors, enhanced oxidative stress is a
novel risk factor of CAD. Increased oxidative stress is asso-
ciated with the pathogenesis of CAD [11–14]. Clinical trials
have revealed that oxidative stress may increase free oxygen
reactive species (ROS) formation and reduce antioxidant
defenses [11, 12]. Antioxidant enzymes such as catalase
(CAT), superoxide dismutase (SOD), and glutathione per-
oxidase (GPx) are the ﬁrst line of defense against ROS, and2 The Scientiﬁc World Journal
a decrease in their activities contributes to the oxidant attack
oncells,especiallyinindividualssuﬀeringfromCAD[15].As
a result, we designed a case-control study to investigate the
relationship between coenzyme Q10 concentration and oxi-
dativestress,aswellasantioxidantenzymesactivities;wealso
examined the association between coenzyme Q10 and the
risk of CAD.
2.MaterialsandMethods
2.1. Subjects. The current study was designed as a case-con-
trol study. CAD patients were recruited from the cardiology
clinic of Taichung Veterans General Hospital in Taiwan. Pa-
tients who were identiﬁed by cardiac catheterization as
having at least 50% stenosis of one major coronary artery or
receiving percutaneous transluminal coronary angioplasty
(PTCA) were assigned to the case group (n = 51). Case sub-
jects with diabetes, liver, renal diseases, or undergoing statin
therapywereexcluded.Noneofoursubjectshadexperienced
anacutemyocardialinfarctionwithintheprevious6months.
Control subjects were recruited from the physical examina-
tion unit of Taichung Veterans Hospital. Control subjects
did not have any illnesses and a history of gastrointestinal
disorder, cardiovascular disease (showed normal electrocar-
diogram), hypertension, hyperlipidemia, liver and renal dis-
ease, diabetes, cancer, alcoholism, or other metabolic disease
and exhibited normal blood biochemical values, including
fasting blood glucose < 6.11mmol/L, blood urea nitrogen
(BUN) < 7.9mmol/L, creatinine < 123.8μmol/L, alkaline
phosphates < 190U/L, glutamic oxaloacetic transaminase
(GOT)<35U/L,andglutamicpyruvatetransaminase(GPT)
< 45U/L. Subjects currently taking antioxidant vitamin sup-
plementswerealsoexcluded.Informedconsentwasobtained
from each subject. This study was approved by the Institu-
tional Review Board of Taichung Veterans General Hospital
in Taiwan. The age, blood pressures, and smoking habits of
a l ls u b j e c t sw e r er e c o r d e d .B l o o dp r e s s u r ew a sm e a s u r e di n
each patient after resting for at least 5min. Body weight,
height, waist, and hip circumferences were measured and the
bodymassindex(kg/m2)andthewaisttohipratiowerethen
calculated.
2.2. Blood Collection and Biochemical Measurement. Fasting
venous blood samples (15mL) were obtained to estimate
hematologicalandvitaminstatus.Bloodspecimenswerecol-
lected in Vacutainer tubes (Becton Dickinson, Rutherford,
NJ, USA) with or without containing EDTA as an antico-
agulant as needed. Serum and plasma were prepared and
t h e nf r o z e n( −80◦C) for storage until analysis. Hemato-
logical parameters (i.e., serum creatinine, total cholesterol,
triacylglycerol, LDL-C, high density lipoprotein-cholesterol
(HDL-C)) were measured using an automated biochemical
analyzer.
Plasma coenzyme Q10 was measured using high-per-
formance liquid chromatography (HPLC) according to the
method of Chu et al. [16] and Littarru et al. [17]. The mean
intra- and interassay coeﬃcients of fasting plasma coenzyme
Q10 variability were 1.8% and 4.4%, respectively. The mean
analytical recovery of plasma coenzyme Q10 was 99.8%.
Plasma MDA was determined using the thiobarbituric acid
reactive substances (TBARs) method, as described by Bot-
soglou et al. [18] and Chung et al. [19]. The mean intra- and
interassay coeﬃcients of plasma MDA variability were 1.9%
and 3.9%, respectively. Red blood cells (RBCs) were diluted
with 25x sodium phosphate buﬀer for SOD and GPx mea-
surements and 250x sodium phosphate buﬀer for CAT mea-
surement. The methods for measuring CAT, SOD, and GPx
in RBCs have previously been described [19]a n dm e a s u r e -
ments were performed spectrophotometrically at 240nm,
325nm, and 340nm, respectively. Protein contents of RBCs
were determined based on the Biuret reaction of the BCA kit
(Thermo, Rockford, IL, USA). The mean intra- and interas-
say coeﬃcients of protein variability were 0.2% and 3.3%,
respectively,inRBCs.Theantioxidantenzymesactivitylevels
were expressed as unit/mg of protein. All analyses were
performed in duplicate and the variations of repeated de-
terminations were within 10% of the same sample. The an-
alyses of plasma MDA and antioxidant enzymes activities
were completed within 7 days.
2.3. Statistical Analyses. Data were analyzed using SigmaS-
tat statistical software (version 2.03; Jandel Scientiﬁc, San
Rafael, CA, USA). The normal distribution of variables was
evaluatedusingtheKolmogorov-Smirnovtest.Diﬀerencesin
subjects’ demographic data and the hematological measure-
ment data between case and control groups were analyzed
using the Student’s t-test or the Mann-Whitney rank sum
test. For categorical response variables, diﬀerences between
two groups were assessed using the Chi-square test or the
Fisher’sexacttest.Toexaminetherelationshipsoftheplasma
coenzyme Q10 concentration and the ratio of coenzyme
Q10 to lipid proﬁles with oxidative stress (MDA) and anti-
oxidant enzymes activities (CAT, SOD, GPx), multiple linear
regression analyses were used. We adjusted the potential
confounders of CAD, including age, gender, systolic blood
pressure, waist to hip ratio, creatinine, and smoking. Ad-
justed odds ratios (ORs) with 95% conﬁdence intervals
(CI) for CAD were calculated from the logistic regression
models based on the fourth level (75th percentile) of plasma
coenzyme Q10 and the fourth level (75th percentile) of the
ratio of coenzyme Q10 to lipid proﬁles. Data were expressed
as means ± standard deviations, and results were considered
statistically signiﬁcant at P<0.05.
3. Results
Table 1 shows the demographic data and health character-
istics of the subjects. Subjects in the case group had signif-
icantly higher values for the number of males, age, systolic
blood pressure, body mass index, waist to hip ratio, hemato-
logical parameters (i.e., creatinine, LDL-C, TC/HDL-C), and
lower HDL-C level than the control group.
The plasma coenzyme Q10 concentration, lipid perox-
idation and antioxidant enzymes activities are shown in
Figures1and2.Subjectsinthecasegrouphadsigniﬁcantde-
creases in the plasma coenzyme Q10 concentration (P<
0.01) and the ratio of coenzyme Q10 to lipid proﬁles (P<
0.01). The value of MDA was signiﬁcant higher in the caseThe Scientiﬁc World Journal 3
Table 1: Characteristics of subjects.
Case (n = 51) Control (n = 102) P values
Male/female (n) 47/4 52/50 <0.01
Age (y) 75.2 ± 8.61 (77.0) 49.8 ± 8.3 (50.0) <0.01
Systolic blood pressures (mmHg) 133.3 ± 8.6 (130.0) 118.6 ± 8.6 (120.0) <0.01
Diastolic blood pressure (mmHg) 74.1 ± 10.0 (70.0) 76.0 ± 8.2 (77.0) 0.06
Body mass index (kg/m2) 25.6 ± 3.1 (25.2) 24.4 ± 3.5 (24.1) 0.03
Waist to hip ratio 0.93 ± 0.1 (0.93) 0.85 ± 0.1 (0.87) <0.01
Creatinine (μmol/L) 114.9 ± 26.5 (106.1) 88.4 ± 26.5 (88.4) <0.01
TC (mmol/L) 4.9 ± 0.9 (4.7) 5.1 ± 0.9 (5.2) 0.16
TG (mmol/L) 1.5 ± 0.9 (1.3) 1.5± 0.9 (1.4) 0.85
LDL-C (mmol/L) 3.2 ± 0.8 (3.0) 2.9 ± 0.8 (2.9) <0.05
HDL-C (mmol/L) 1.0 ± 0.2 (1.0) 1.4 ± 0.4 (1.3) <0.01
TC/HDL-C 5.4 ± 1.6 (5.0) 3.9 ± 1.2 (3.9) <0.01
Current smoker2, n (%) 10 (19.6%) 13 (12.7%) 0.38
1Mean ±SD (median).
2Current smoker: individuals currently smoking one or more cigarettes per day.
HDL-C: high density lipoprotein-cholesterol; LDL-C: low density lipoprotein-cholesterol; TC: total cholesterol; TG: triglyceride.
Table 2: Correlations between plasma coenzyme Q10 and the ratios of coenzyme Q10 to lipid proﬁles, lipid peroxidation, and antioxidant











Model 12 −0.72 (<0.05) −3.81 (0.03) −0.22 (0.30) −2.16 (0.02)
Model 23 −0.02 (0.96) −0.69 (0.70) −0.01 (0.97) −0.02 (0.99)
Model 34 −0.06 (0.87) −0.75 (0.68) 0.02 (0.93) −0.00 (1.00)
CAT (U/mg protein)
Model 1 99.23 (<0.01) 502.66 (<0.01) 46.72 (0.03) 276.78 (<0.01)
Model 2 54.09 (0.13) 293.29 (0.08) 26.74 (0.19) 137.34 (0.16)
Model 3 44.31 (0.22) 233.31 (0.18) 16.24 (0.47) 115.06 (0.25)
SOD (U/mg protein)
Model 1 −14.77 (<0.01) −63.53 (<0.01) −8.95 (<0.01) −38.12 (<0.01)
Model 2 −12.51 (<0.01) −51.66 (0.01) −7.87 (<0.01) −32.15 (<0.01)
Model 3 −12.16 (<0.01) −50.85 (0.01) −8.31 (<0.01) −32.20 (<0.01)
GPx (U/mg protein)
Model 1 2.22 (<0.01) 8.45 (0.04) 0.69 (0.15) 5.02 (0.02)
Model 2 0.08 (0.92) −1.50 (0.69) −0.11 (0.79) −1.89 (0.39)
Model 3 0.03 (0.98) −1.58 (0.69) −0.34 (0.47) −2.04 (0.37)
1Regression coeﬃcient (N = 153).
2None adjusted.
3Adjusted for age and gender.
4Same as for model 2 and also adjusted for systolic blood pressure, waist to hip ratio, creatinine, and smoking.
CAT: catalase activity; GPx: glutathione peroxidase; LDL-C: low density lipoprotein-cholesterol; MDA: malondialdehyde; SOD: superoxide dismutase; TC:
total cholesterol; TG: triglyceride.
group(P<0.01). With regard to the levels of antioxidant en-
zymes, subjects in the case group had signiﬁcant lower CAT
(P<0.01) and GPx activities (P<0.01) but higher SOD ac-
tivities (P<0.01) than the control group.
The correlations between coenzyme Q10 concentration,
lipid peroxidation, and antioxidant enzymes activities are
shown in Table 2. The MDA level was signiﬁcantly negative
correlatedwiththeplasmacoenzymeQ10concentration(β =
−0.72, P<0.05) and the ratio of coenzyme Q10, but the
statistical signiﬁcance were disappeared after adjusting for
age and gender or the potential confounders of CAD.









































































































































Figure 1: Concentrations of plasma coenzyme Q10 and the ratios of coenzyme Q10 to lipid proﬁles. ∗Values were signiﬁcantly diﬀerent
between case and control groups; P<0.01. LDL-C: low density lipoprotein-cholesterol; TC: total cholesterol; TG: triglyceride.
coenzyme Q10 to lipid proﬁles were signiﬁcantly positively
correlated with CAT and GPx activities but signiﬁcantly neg-
atively correlated with SOD activities. However, the corre-
lations were not signiﬁcant after adjusting for the potential
confounders of CAD with the exception of SOD.
Furthermore, we calculated the ORs of CAD based
on the fourth level (75th percentile) of plasma coenzyme
Q10 concentration and the fourth level (75th percentile) of
the ratio of coenzyme Q10 to lipid proﬁles (Table 3). Sub-
jects with higher plasma coenzyme Q10 (≥0.52μmol/L) or
with a higher ratio of coenzyme Q10 to lipid proﬁles (co-
enzyme Q10/TC ≥ 0.10μmol/mmol, coenzyme Q10/TG ≥
0.52μmol/mmol and coenzyme Q10/LDL-C ≥ 0.18μmol/
mmol) had signiﬁcant reductions in the risk of CAD.
4. Discussion and Conclusion
The present study showed the plasma coenzyme Q10 con-
centration had statistically signiﬁcant reductions in the risk
CAD. In Table 3, subjects with a higher coenzyme Q10 con-
centration (≥0.52μmol/L) and a higher ratio of coenzyme
Q10 to lipid proﬁles (coenzyme Q10/TG ≥ 0.52μmol/mmol
and coenzyme Q10/LDL-C ≥ 0.18μmol/mmol) showed a
signiﬁcantly lower risk of CAD even after adjusting for age,
gender, and the potential confounders of CAD. This re-
sult is similar to a cohort study conducted by Molyneux et al.
[20], that followed patients for 2.69 years and suggested
that the plasma coenzyme Q10 concentration (either 0.68






































































































Figure 2: Concentration of lipid peroxidation and antioxidant enzymes activities. ∗Values were signiﬁcantly diﬀerent between case and
control groups; P<0.01. CAT: catalase; GPx: glutathione peroxidase; MDA: malondialdehyde; SOD: superoxide dismutase.
the mortality of patients with chronic heart failure. Patients
with lower coenzyme Q10 concentration might have com-
promised mitochondrial function and correlating to the
severity of disease [20]. The cut-oﬀ point of plasma coen-
zyme Q10 (0.52μmol/L) in this study is also similar with the
CORONA (Controlled Rosuvastatin Multinational Study in
Heart Failure) trial conducted by McMurray et al. [21], the
mortality was signiﬁcantly increased in the lowest level of
coenzyme Q10 (0.49μmol/L) in a univariate analysis but not
in a multivariable analysis. The plasma coenzyme Q10 con-
centration has been shown to be reduced under statin thera-
py [21, 22], and we therefore excluded patients who were be-
ing treated with statin from this study, and we found that the
low coenzyme Q10 level could be a signiﬁcant predictor of
increased CAD risk in a multivariable analysis, even after ad-
justment for the lipid proﬁles (LDL-C or TC/HDL-C, P =
0.01) (data not shown).
AlthoughourCADsubjectswerestableandhadnoexpe-
rience of acute myocardial infarction within the previous
6 months, their plasma coenzyme Q10 concentration was
signiﬁcantly lower than that of control subjects (Figure 1)
and the reference values (0.46μmol/L) [23]. Patient suﬀering
from CAD might suﬀer loss of coenzyme Q10 under higher
oxidative stress [11–14]. Subjects in the case group showed
a signiﬁcant higher lipid peroxide (MDA) level than control
(Figure 2, P<0.01), which is an indicator of free radical-
induced damage during myocardial ischemia [24, 25]. There
was a signiﬁcant negatively correlations between the plasma
coenzyme Q10 and MDA levels (Table 2,M o d e l1 ) ,b u tt h e
statistical signiﬁcance disappeared after adjusting for the
potential confounders of CAD (Table 2,M o d e l s2a n d3 ) .
In addition to oxidative stress, we assessed the activities of
the major antioxidant enzymes directly involved in the neu-
tralization of ROS. The activities of CAT and GPx were6 The Scientiﬁc World Journal
Table 3: The odds ratios of coronary artery disease based on the concentrations of coenzyme Q10 and the ratios of coenzyme Q10 to the
lipid proﬁles.
Odds ratio (95% CI) P value
Coenzyme Q10 < 0.52μmol/L 1.00 —
Coenzyme Q10 ≥ 0.52μmol/L
Model 11 0.08 (0.02–0.36) <0.01
Model 22 0.11 (0.11–0.90) 0.04
Model 33 0.03 (0.00–0.49) 0.01
Coenzyme Q10/TC < 0.10μmol/mmol 1.00 —
Coenzyme Q10/TC ≥ 0.10μmol/mmol
Model 1 0.14 (0.05–0.43)) <0.01
Model 2 0.24 (0.04–1.56) 0.14
Model 3 0.27 (0.04–1.91) 0.19
Coenzyme Q10/TG < 0.52μmol/mmol 1.00 —
Coenzyme Q10/TG ≥ 0.52μmol/mmol
Model 1 0.19 (0.07–0.52) <0.01
Model 2 0.03 (0.00–0.35) <0.01
Model 3 0.03 (0.00–0.51) 0.02
Coenzyme Q10/LDL-C < 0.18μmol/mmol 1.00 —
Coenzyme Q10/LDL-C ≥ 0.18μmol/mmol
Model 1 0.10 (0.03–0.35) <0.01
Model 2 0.05 (0.01–0.47) <0.01
Model 3 0.06 (0.01–0.62) 0.02
1None adjusted.
2Adjusted for age and gender.
3Same as for model 2 and also adjusted for systolic blood pressure, waist to hip ratio, creatinine and smoking.
CI: conﬁdence interval; LDL-C: low density lipoprotein-cholesterol; TC: total cholesterol; TG: triglyceride.
signiﬁcantly lower in the case group compared to those of
the control group (Figure 2). As shown in Table 2, there
was a signiﬁcantly positive relationship between the levels of
plasma coenzyme Q10 and CAT or GPx (Model 1), which
disappeared after adjusting for age, gender or other potential
confoundersofCAD(Model2and3).Ontheotherhand,the
activities of SOD were signiﬁcantly higher in the case group
and negative correlated with the concentration of plasma
coenzyme Q10, even after adjusting for the potential con-
founders. The role of antioxidant enzymes defense against
the ROS is controversial. In CAD patients, SOD activity may
increase to protect against lipid peroxidation and against
ROS [15, 26]. Coenzyme Q10 may assist SOD in the uptake
of superoxide radical to formoxygen and hydrogenperoxide.
Traditional CAD risk factors such as gender [23]a n da g e
[20, 21, 23, 27] may also inﬂuence the plasma coenzyme
Q10 concentration. In present study, males (β = −0.11, P<
0.01) and older patients (β = −0.01, P<0.01) had signif-
icantly lower levels of plasma coenzyme Q10 in the case
group compared to those in the control group. Other CAD
risk factors such as blood pressure [28], obesity [21, 29], and
smoking [30] may also aﬀect coenzyme Q10 concentration.
We have examined the correlations between the plasma co-
enzyme Q10 concentration and blood pressure, waist to hip
ratio, or smoking habits (data not shown). There was a sig-
niﬁcantly negative correlation between the plasma coenzyme
Q10 concentration and systolic blood pressure (β = −0.00,
P = 0.01), smoking (β = −0.10, P = 0.04), and waist to hip
ratio (β = −0.26, P = 0.09). Therefore, we presume that the
plasma coenzyme Q10 level was lower in the case group due
to oxidative stress and the traditional CAD risk factors.
Coenzyme Q10 is a lipid-soluble antioxidant, that is,
transported by lipids and lipoprotein (especially LDL-C,
58%) in the blood [31]. Therefore, the value of plasma co-
enzyme Q10 was normalized relative to the lipid proﬁles,
includingTC,TG,orLDL-C,toprovideaccurateassessments
of the amount of plasma coenzyme Q10 [32]. After was lipid
normalized, the ratios were signiﬁcantly lower in the case
group compared to those in the control group (Figure 1).
Thecorrelations betweenthe ratios ofcoenzyme Q10tolipid
proﬁles and antioxidant enzymes activities were similar to
plasmacoenzymeQ10withoutlipidnormalization(Table 2).
In addition, a higher ratio of coenzyme Q10 to TG or LDL-
C showed a signiﬁcant lower value for the risk of CAD
(Table 3). Our results support the potential cardioprotective
impact of coenzyme Q10.
Few studies have investigated the relation between plas-
ma coenzyme Q10 and racial diﬀerence, especially in Asian
population. An observational study was conducted by Hug-
hes et al. [33] reported Indian males had a signiﬁcantly low-
er level of plasma coenzyme Q10 than Chinese male and may
contribute the higher susceptibility of this ethnic groupThe Scientiﬁc World Journal 7
to coronary heart disease. The racial diﬀerence in lifestyle
and nutritional patterns may partly explain the diﬀerent
plasma coenzyme Q10 level [33] .I nt h i ss t u d y ,w eh a v e
assessed the nutrients intake of all subjects base on 24-h re-
call (data not shown). Because of the insuﬃcient nutrient
databases, we cannot assess coenzyme Q10 intake from 24-
h dietary recall, but our CAD subjects had signiﬁcantly lower
antioxidants intake (such as vitamins A and E) than the con-
trol. An increase in the concentration of coenzyme Q10 may
somehow aﬀect the mitochondrial respiratory function [34]
and increase the antioxidants activities [35, 36]; as a result,
early supplementation should be administrated in cases of
deﬁciency [36].
Our study has two limitations. First, the number of pa-
rticipants was small, although we did recruit more subjects
than we expected to recruit (sample size calculation: we ex-
pected the diﬀerences in mean levels of plasma coenzyme
Q10 between case and control groups were to be 0.2 ±
0.3μmol/L, hence the desired power was set at 0.8 to detect a
true eﬀect, and α = 0.05 with a minimal simple size of
40 participants in each group). Second, this study was the
absence of age and gender matched between case and control
groups; as a result, we try to limit these biases by adjusting
for the potential confounders of CAD in statistical tests. La-
ger studies are needed to establish the beneﬁcial eﬀect of co-
enzyme Q10 in CAD patients.
Patients with CAD were exposed to a higher level of oxi-
dative stress and a lower coenzyme Q10 concentration. Our
results indicate a strong correlation between the plasma co-
enzyme Q10 and reductions in the risk of CAD. It might
beneﬁt in administration of coenzyme Q10 to CAD patients,
especially those with low coenzyme Q10 level.
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